Results 121 to 130 of about 165,244 (251)

Systemic Lupus Erythematosus [PDF]

open access: yesPostgraduate Medical Journal, 1958
T F, McCARTHY, D P, MISRA
openaire   +2 more sources

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman   +3 more
wiley   +1 more source

Surgical management of persistent gingival recession after sepsis‐associated gingival necrosis in a patient with systemic lupus erythematosus: A case report

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Sepsis‐associated gingival necrosis is an uncommon oral manifestation that may result in extensive gingival recession after the resolution of the acute phase. Methods This report presents the 2‐year follow‐up of periodontal management in a 38‐year‐old woman with systemic lupus erythematosus, who developed septic shock accompanied by
Risako Mikami   +4 more
wiley   +1 more source

Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pre‐eclampsia is a hypertensive disorder of pregnancy affecting 3–8% of pregnancies worldwide, with no disease‐modifying therapy currently available. Drug repurposing offers a promising strategy, yet no candidate has been validated to date. Pregnancy‐associated physiological changes alter drug pharmacokinetics (PK), and pre‐eclampsia itself may further
Cassius M. Phogole   +4 more
wiley   +1 more source

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

open access: yes
Arthritis &Rheumatology, EarlyView.
Kerem Abacar   +5 more
wiley   +1 more source

A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Natural killer (NK) cell neoplasms span indolent to highly aggressive entities, and flow cytometric immunophenotyping is central to their detection and classification. However, distinguishing reactive from neoplastic NK cell expansions can be challenging because NK cells lack somatically recombined antigen receptors, and reactive states may ...
Aaron J. Wilk   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy